Evidence map›Paper›PMID 38920554›Full record

ArticleDiseases (Basel, Switzerland)2024

Impact of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study.

Naotaka Kumada, Koji Iinuma, Yasuaki Kubota, Kimiaki Takagi, Masahiro Nakano, Takashi Ishida, Shigeaki Yokoi, Fumiya Sugino, Makoto Kawase, Shinichi Takeuchi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Naotaka KumadaDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.ORCID 0009-0006-1993-5393
Koji IinumaDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.ORCID 0000-0002-0362-8624
Yasuaki KubotaDepartment of Urology, Toyota Memorial Hospital, 1-1 Heiwacho, Toyota 471-8513, Japan.
Kimiaki TakagiDepartment of Urology, Daiyukai Hospital, 1-9-9 Sakura, Ichinomiya 491-8551, Japan.ORCID 0000-0003-2774-925X
Masahiro NakanoDepartment of Urology, Gifu Prefectural General Medical Center, 4-6-1 Noisiki, Gifu 500-8717, Japan.
Takashi IshidaDepartment of Urology, Gifu Municipal Hospital, 7-1 Kashimacho, Gifu 500-8513, Japan.
Shigeaki YokoiDepartment of Urology, Central Japan International Medical Center, Minokamo 505-8510, Japan.
Fumiya SuginoDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Makoto KawaseDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.ORCID 0000-0001-7269-2462
Shinichi TakeuchiDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Kota KawaseDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Daiki KatoDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Manabu TakaiDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Yuki TobisawaDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Takayasu ItoCenter for Clinical Training and Career Development, Graduate School of Medicine, Gifu University, Gifu 501-1194, Japan.
Keita NakaneDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.
Takuya KoieDepartment of Urology, Graduate School of Medicine, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan.ORCID 0000-0002-2980-127X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we aimed to determine the utility of cytoreductive nephrectomy (CN) in real-world clinical practice and investigate whether CN contributes to improved oncological outcomes in patients with metastatic renal cell carcinoma (mRCC). This retrospective multicenter cohort study enrolled patients with mRCC who received systemic therapy at six institutions between May 2005 and May 2023. The patients were divided into those who did not undergo CN (Group I) and those who underwent CN (Group II). The primary endpoints were oncological outcomes, including cancer-specific survival (CSS) and progression-free survival (PFS). Altogether, 137 patients with mRCC were included in this study. The median CSS was 14 months in Group I and 32 months in Group II (

Indexed as

cytoreductive nephrectomyimmune checkpoint inhibitorsimmune checkpoint inhibitors-based combination therapymetastatic renal cell carcinomatargeted therapy

Identifiers

PMID38920554
PMCPMC11202703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.